Clinical Trials on Small Cell Lung Cancer (SCLC)

Total 15096 results

Hoffmann-La Roche

Recruiting

A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy (SKYSCRAPER-15)

Non-small Cell Lung Cancer (NSCLC)

Korea, Republic of, United States, China, Japan, Australia, Taiwan, Brazil, Argentina, Hong Kong
Servier Bio-Innovation LLC
Regeneron Pharmaceuticals; Institut de Recherches Internationales Servier

Not yet recruiting

Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer (NSCLC)

Hong Kong, United States, Australia
Jinming Yu

Recruiting

Real-World Study of Iruplinalkib in the Treatment of ALK-Positive Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC)

China
Pingping Song

Not yet recruiting

Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer

Non-Small Cell Lung Cancer(NSCLC)

China
Jinming Yu

Recruiting

WX-0593 Combined With Concurrent Chemoradiotherapy in Unresectable Locally Advanced NSCLC

Non-small Cell Lung Cancer (NSCLC)

China
Shanghai Miracogen Inc.

Not yet recruiting

A Study of MRG002 in the Treatment of Patients With HER2-mutated Unresectable/Metastatic Non-small Cell Lung Cancer (NSCLC).

Non-small- Cell Lung Cancer (NSCLC)

China
BeiGene

Recruiting

A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

NSCLC | Non-small Cell Lung Cancer

Japan, United States, France, Mexico, Germany, Argentina, Brazil, Korea, Republic of, Turkey
Daiichi Sankyo
Merck Sharp & Dohme LLC; AstraZeneca

Recruiting

HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer (NSCLC)

United States, Korea, Republic of, Taiwan, Japan
Daiichi Sankyo

Recruiting

HER3-DXd in Metastatic or Unresectable Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer (NSCLC)

United States, Korea, Republic of, Spain, Japan, Netherlands, Taiwan
Hoffmann-La Roche

Active, not recruiting

A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer (SKYSCRAPER-06)

Non-small Cell Lung Cancer (NSCLC)

United States, Korea, Republic of, Canada, Belgium, China, Denmark, Spain, Thailand, United Kingdom, Taiwan, Brazil, Germany, Mexico, Italy, Switzerland, Hong Kong, Japan, France, Turkey, New Zealand, Poland
Novartis Pharmaceuticals

Active, not recruiting

Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation (GeoMETry-C)

Non-Small Cell Lung Cancer (NSCLC)

China
AstraZeneca

Active, not recruiting

Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION) (ORION)

Non-small Cell Lung Cancer NSCLC

United Kingdom, Belgium, United States, Korea, Republic of, Hungary, Japan, Russian Federation, Poland, Ukraine, India, Mexico, Netherlands
University of Texas Southwestern Medical Center
AstraZeneca

Active, not recruiting

Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC

Non-small Cell Lung Cancer (NSCLC)

United States
Novartis Pharmaceuticals

Terminated

Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50%

Non-small Cell Lung Cancer (NSCLC)

Japan, Germany, Spain, Italy, France, Thailand, Belgium, Netherlands, India, Malaysia, Taiwan, Australia, Canada, Czechia, Greece, Hong Kong
Abramson Cancer Center at Penn Medicine

Completed

Phase II Study of Pembrolizumab After Curative Intent Treatment for Oligometastatic Non-Small Cell Lung Cancer

Oligometastatic Non-small Cell Lung Cancer (NSCLC)

United States
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

Efficacy and Safety of IBI110 in Combination With Sintilimab Versus Sintilimab Alone in Neoadjuvant and Adjuvant Therapy of Radically Resectable Non-small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC)

China
Incyte Corporation

Completed

Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration (FIGHT-210)

Non-Small Cell Lung Cancer (NSCLC)

Spain, United States, Italy, Germany, France
Takeda

Completed

A Spanish Medical Record Review of Clinical Characteristics and Outcomes in Non-small Cell Lung Cancer Participants With EGFR Exon 20 Insertion (ermEX-20)

Non-small Cell Lung Cancer (NSCLC)

Spain
G1 Therapeutics, Inc.

Terminated

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4) (PRESERVE 4)

NSCLC | Lung Cancer | Metastatic Non-Small Cell Lung Cancer

United States
Takeda

Completed

A Chart Review Study of Adults With Advanced NSCLC (EXTRACT)

Non-small Cell Lung Cancer (NSCLC)

Hong Kong, France, Canada
Albert Einstein College of Medicine
Celldex Therapeutics

Completed

FLT3 Ligand Immunotherapy and Stereotactic Radiotherapy for Advanced Non-small Cell Lung Cancer (FLT3)

Non-small Cell Lung Cancer (NSCLC)

United States
Daiichi Sankyo, Inc.

Terminated

DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC)

Taiwan
Hoffmann-La Roche

Withdrawn

A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC)
Novartis Pharmaceuticals

No longer available

Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC

Non-small Cell Lung Cancer (NSCLC)

United States, Argentina, Korea, Republic of, Hong Kong, Thailand, Mexico, Jordan, Colombia, India, Philippines
AstraZeneca

Completed

Study to Evaluate Concordance of Detecting EGFR (Epidermal Growth Factor Receptor) Mutation by Circulating Tumour Free DNA Versus Tissues Biopsy in NSCLC (Non-small Cell Lung Cancer). (CONCORDANCE)

NSCLC (Non-small Cell Lung Cancer)

India
Celgene

Completed

An Open Label Study in Patients With Advanced NSCLC With ABI-007(Abraxane) in Combination With Carboplatin

Non-Small Cell Lung Cancer (NSCLC)

Russian Federation
MedImmune LLC

Completed

A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer (D4190C00006)

NSCLC | Lung Cancer | Non-small Cell Lung Cancer

United States, France, Italy, Spain, Belgium, United Kingdom, Korea, Republic of, Australia, Taiwan
Theresa Whiteside, PhD
Immune Cell Therapy Inc.

Terminated

Immunization of Patients With Non Small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer (NSCLC)

United States
Astellas Pharma Global Development, Inc.

Terminated

A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations (SOLAR)

Non-small Cell Lung Cancer (NSCLC)

United States, Australia, Belgium, Canada, Chile, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Malaysia, Netherlands, Peru, Portugal, Romania, Russian Federation, Singapore, Spain, Taiwan, Thailand, Ukraine, United Kingdom
Astellas Pharma Inc

Completed

Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene

NSCLC | Non Small Cell Lung Cancer

United States, Canada, Korea, Republic of, Singapore, Thailand, Hong Kong
Recombio SL
Eurofarma Laboratorios S.A.; Laboratorio Elea Phoenix S.A.; Innogene Kalbiotech... and other collaborators

Unknown

Immunotherapy With Racotumomab in Advanced Lung Cancer

NSCLC | Lung Cancer, Non-small Cell

Brazil, Indonesia, Argentina, Cuba, Philippines, Singapore, Thailand
TTY Biopharm

Completed

A Study of TS-1 Plus Cisplatin in Patients With Advanced Non-small-cell Lung Cancer

Non-small-cell Lung Cancer (NSCLC)

Taiwan
AbbVie (prior sponsor, Abbott)

Completed

A Phase 1/2 Study Evaluating ABT-751 in Combination With Alimta in Advanced Non-Small Cell Lung Cancer

NSCLC | Lung Cancer | Non-Small-Cell Lung Cancer

United States, Czech Republic, Greece, Hungary, Netherlands, Slovakia
National Taiwan University Hospital

Unknown

e- Ab Sensor-based Real-time Detection of Mutant EGFR in Clinical Specimens From Patients of Non-small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC)

Taiwan
Pfizer

Terminated

A Study In Patients Who Will Undergo Surgical Removal Of Non-Small Cell Lung Cancer To Evaluate Molecular Changes That Occur In Tumor Tissue After Short Term Exposure To PF-00299804

Non-Small Cell Lung Cancer (NSCLC)

United States
AbbVie
Pfizer

Active, not recruiting

An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer

Cancer | Non-small Cell Lung Cancer (NSCLC)

United States, Israel, Japan, Korea, Republic of, Spain, Taiwan
University Hospital, Essen

Recruiting

Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients (NEOpredict)

NSCLC, Stage I | NSCLC Stage II | NSCLC, Stage IIIA

Belgium, Germany, Netherlands
Second Affiliated Hospital, School of Medicine,...
Tongji Hospital; Qilu Hospital of Shandong University; First Hospital of China... and other collaborators

Recruiting

A Study With Pembrolizumab for Non-small Cell Lung Cancer (NSCLC)

Pembrolizumab | Non-small-lung-cell Cancer, NSCLC

China
Beijing Haidian Hospital
307 Hospital of PLA; Peking University People's Hospital; 309th Hospital of Chinese...

Recruiting

The Role of Icotinib in the Perioperative Treatment of IIIA - IIIB NSCLC Patients With EGFR Mutation

Non-small Cell Lung Cancer(NSCLC)

China
Johns Hopkins University
AstraZeneca

Enrolling by invitation

ROSE for Improved Molecular Marker Testing Via EBUS (ROSE/NoROSE)

Non-small Cell Lung Cancer (NSCLC)

United States
Albert Einstein College of Medicine
Montefiore Medical Center

Active, not recruiting

The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial. (SPRINT)

Non-small Cell Lung Cancer, NSCLC

United States
Fondazione IRCCS Istituto Nazionale dei Tumori,...

Active, not recruiting

Pembrolizumab in First Line Treatment of Advanced NSCLC Patients With PD-L1 Low Tumors. (PEOPLE)

Non Small Cell Lung Cancer (NSCLC)

Italy
Abramson Cancer Center of the University of Pennsylvania

Terminated

Serial [18F]Fluorodeoxyglucose ([18F]FDG )PET/CT as a Biomarker of Therapeutic Response in Anti-PD1/PDL1 Therapy

Non-Small Cell Lung Cancer (NSCLC)

United States
AstraZeneca

Approved for marketing

Open Label Extension Study With Gefitinib (IRESSA™) for Completing Trial Patients Who May Benefit From Further Treatment

Non Small Cell Lung Cancer (NSCLC)

Taiwan, Thailand, Turkey, Brazil, Philippines, Russian Federation, Romania, Austria, Hungary, Bulgaria, Latvia, India, Argentina, Australia, Estonia, Malaysia, Mexico, Singapore, South Africa
Qianfoshan Hospital

Recruiting

Patient's Whole Process Follow-up Management(HOPE-1) (HOPE-1)

Metastatic NSCLC | Locally Advanced Non-Small Cell Lung Cancer

China
Armando Santoro, MD

Completed

Pemetrexed in Advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC)

Italy
Bioven Sdn. Bhd.

Terminated

Vaccine Therapy in Treating Patients With Non-Small Cell Lung Cancer (NSCLC) Stages IIIB/IV (NSCLC)

Non-small-cell Lung Cancer (NSCLC) Stage IIIb/IV

Malaysia
Joel Neal

Terminated

Phase 2a Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors

Neuroendocrine Tumors | Small Cell Lung Cancer (SCLC)

United States
National Cancer Institute (NCI)

Recruiting

Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

EGFR-Mutated Non-Small-Cell Lung Carcinoma | Small Cell/Neuroendocrine

United States
AbbVie

Available

Expanded Access to Telisotuzumab Vedotin

Non-Small Cell Lung Cancer (NSCLC)

Australia, Hong Kong, Israel, United States, Germany

Clinical Trials on Small Cell Lung Cancer (SCLC)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Argentina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations